PRFX
PainReform·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Stock Price Surged Significantly
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRFX
Painreform Ltd
A clinical stage specialty pharmaceutical company focused on providing an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates
65 Yigal Alon St., Tel Aviv 6744316, Israel
--
PainReform Ltd was incorporated and started business in November 2007. The company is a clinical-stage specialty pharmaceutical company focused on the reformulation of existing therapies. The Company's proprietary drug sustained-release system extends the in vivo activity of APIs (active drug ingredients), thereby increasing the therapeutic window for patient treatment.
Company Financials
EPS
PRFX has released its 2023 Q3 earnings. EPS was reported at 0.48, versus the expected 0, beating expectations. The chart below visualizes how PRFX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
